Skip to main content
Top
Published in:

02-04-2022 | Multiple Sclerosis | Neurological Update

Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies

Authors: Marijne Vandebergh, Nicolas Degryse, Bénédicte Dubois, An Goris

Published in: Journal of Neurology | Issue 8/2022

Login to get access

Abstract

Multiple sclerosis (MS) is a complex disease with both genetic variants and environmental factors involved in disease susceptibility. The main environmental risk factors associated with MS in observational studies include obesity, vitamin D deficiency, Epstein-Barr virus infection and smoking. As modifying these environmental and lifestyle factors may enable prevention, it is important to pinpoint causal links between these factors and MS. Leveraging genetics through the Mendelian randomization (MR) paradigm is an elegant way to inform prevention strategies in MS. In this review, we summarize MR studies regarding the impact of environmental factors on MS susceptibility, thereby paying attention to quality criteria which will aid readers in interpreting any MR studies. We draw parallels and differences with observational studies and randomized controlled trials and look forward to the challenges that such work presents going forward.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies
Authors
Marijne Vandebergh
Nicolas Degryse
Bénédicte Dubois
An Goris
Publication date
02-04-2022
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 8/2022
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-022-11072-4

EAN 2025

Unlock your free and exclusive access to the latest news and expert interviews from the European Academy of Neurology's annual congress.

Read more

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest